Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies

Autor:	John F. Johanson, Raymond M. Panas, Douglas A. Drossman, Ryuji Ueno, Ronnie Fass, Charles Scott, William D. Chey
Rok vydání:	2009
Předmět:	Adult Male medicine.medical_specialty Constipation Adolescent Rome Administration Oral Placebo Severity of Illness Index law.invention Irritable Bowel Syndrome Young Adult chemistry.chemical_compound Lubiprostone Gastrointestinal Agents Randomized controlled trial law Internal medicine medicine Humans Pharmacology (medical) Alprostadil Defecation Linaclotide Irritable bowel syndrome Aged Aged 80 and over Hepatology business.industry Gastroenterology Middle Aged medicine.disease Surgery Clinical trial Treatment Outcome chemistry Patient Satisfaction Quality of Life Plecanatide Female medicine.symptom business Follow-Up Studies medicine.drug
Zdroj:	Alimentary Pharmacology & Therapeutics. 29:329-341
ISSN:	1365-2036 0269-2813
Popis:	Summary Background Effective treatments for irritable bowel syndrome with constipation (IBS-C) are lacking. Aim To assess the efficacy and safety of lubiprostone in IBS-C. Methods A combined analysis was performed among 1171 patients with a Rome II diagnosis of IBS-C in two phase-3 randomized trials of lubiprostone 8 mcg vs. placebo twice daily for 12 weeks. Using a balanced seven-point Likert scale ranging from significantly relieved (+3), to significantly worse (−3), patients responded on their electronic diary to the question: ‘How would you rate your relief of IBS symptoms over the past week compared to how you felt before you entered the study?’. The primary efficacy endpoint was the percentage of overall responders. Results Using an intent-to-treat analysis with last observation carried forward, a significantly higher percentage of lubiprostone-treated patients were considered overall responders compared with those treated with placebo (17.9% vs. 10.1%, P = 0.001). Patients treated with lubiprostone reported a similar incidence of adverse events to those treated with placebo. Conclusions The percentage of overall responders based on patient-rated assessments of IBS-C symptoms was significantly improved in patients treated with lubiprostone 8 mcg twice daily compared to those treated with placebo. Lubiprostone was well tolerated with a favourable safety profile.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::370f1ebf1696db47121ec7bcb0f22ced https://doi.org/10.1111/j.1365-2036.2008.03881.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.